introduction of new non-pharmacological technology is challenging and the methodology for evaluationg such technologies is much less standardized than when dealing with new pharmacological substances. it is, however, as important to use randomized design with blinded assessment and combine that with prospective population based registries to be able to analyze generalizability.
ruptured aortic aneurysms, elective surgery for large aortic aneurysms etc, etc. There is, however, a problem when new methods appear claiming an effect based on individual and perhaps anecdotal experience, habits and traditions, financial relationship to manufacturers of devices etc. In such cases we must be much stricter in demanding evidence and results from properly designed studies. It must be the obligation of the profession to perform the correct scientific evaluation, comparing the new methodology with the best available established one. At the same time we have to admit some fundamental differences between studying surgical and pharmacological methods, the former carrying immediate and sometimes severerisks, requiring training and entailing acertain degree of craftsmanship. This paper will restrict itself to interventions in patients with diseases usually treated by vascular surgeons, but the examples will have amoregeneral interest. Today there are several challenges which the health cares ystem must handle and which also will force to select methods with the highest available evidence. Such challenges aret he rapid increase in the number of elderly people, usually with good health also in high age but with rapidly increasing demands and often several diseases towards the end of their lives, the increasing number of new diagnostic and technical methods, often sophisticated and expensive, wherenot necessarily thereisacoherence in opinion between manufacturers and the health care system, the exponential increase in information (some 15000 journals with more than a million papers per year), rising public expectations with well-in-Assessment of new technology in medicine deals with a variety of functions: pharmaceuticals, devices, surgical or interventional procedures, diagnostic methods, health promoting techniques etc. When it comes to pharmacological substances the regulatory pattern and requirements are rather well defined, the rules ares trict and the introduction of new agents follows arigorous structure. Concerning devices, the rules have been less strict and until recently it has been possible for individual surgeons to test and implant prostheses, grafts etc. on their responsibility. Today a CE-mark at least gives some guarantee, although without having been tested in proper clinical trials. Regarding interventions, open or minimally invasive, the rules have been even less strict and there has sometimes been introduction of new techniques lead by innovative, enthusiastic and sometimes brave colleagues, often convinced that their ideas were correct in spite of sometimes bad initial results. This can be exemplified by the development of open heart surgery,neurosurgery and transplantation surgery.Itis important to define the level of surgical methodology which cannot be questioned and which has stood the test of time. Much of what we are doing today belongs to this cathegory: osteosynthesis for hip fracture, resection of bowel tumours, urgent surgery for formed patients, non-acceptable global variations in the delivery of health care, and as al imiting factor restricted resources. The motivation to seek best available evidence to guide in the clinical decision making on individual patient care seems undisputable.
DEVElopMEnT of SURgERy
Historically surgery was very much care after injuries and emergency interventions to drain abscesses, to amputate ulcerated or injured legs, to remove bladder stones, to prick cataract etc. It was actually not until the mid 1800's that a more dramatic development of surgery took place, the basis being the rapid acceptance and use of anaesthesia and antisepsis. Many surgical methods came into use through trial and error, by experience and by a reasonable pathophysiological understanding of disease processes. The basis for a number of surgical treatments was established, and as mentioned many of them cannot be questioned as the benefits areobvious.
one example of the importance of pathophysiological understanding can be the creation of an externalinternal bypass to prevent stroke (1), where in fact a channel was opened to the brain without removing the embolic source in the carotid bifurcation. This together with the misconception on the role of haemodynamics instead of embolization motivated the design of the study, the result being higher stroke rate and mortality in the operation group. This made Harry Barnett to state that "microvascular anastomosis is am arvellous technique, but it has failed to emerge as a marvellous treatment" (2). The patho-physiological role of embolization from the carotid bifurcation to cause cererebral infarction had been documented already in the 1930's by the pathologist gösta Hultqvist.
Another recent example of how pathophysiological knowledge may change the surgical panorama is the tremendous decrease in surgery for gastroduodenal ulcer when the infectious etiology became clear, changing the treatment to antibiotics for eradication of helicobacter.onthe other hand, one may wonder what had happened to kidney transplantation with better immunological knowledge at the time it started. At least it would have been delayed for years, although the one-year results in the beginning were rather dismal. Another example is surgery for ruptured aortic aneurysms, where mortality in the beginning was far above 50% and still is around 30% (Swedvasc), but the alternative, not operating, goes with 100% mortality. It would seem important, that a general canon of operations, which is agreed upon today being justified as doing moregood than harm, is defined. Some basic steps in the development of surgical methodology is listed in Table 1 . The clinical evidence hierarchy is headed by systematic reviews, often with metaanalysis, and randomized studies, followed by cohort studies and various case studies.
RAnDoMIzED ConTRollED TRIAlS (RCT)
Af undamental strength with RCT is that it is truly experimental with strict inclusion and exclusion criteria giving ahigh internal validity.Ideally only one factor is varied making true comparison between two alternatives possible. The very strict study design, however,m ay give ap oor external validity,t hat is making the results less generalizable. one problem, further supporting this concern, is the often very slow recruitment rate, not least in multicenter trials. This problem is illustrated in Table 2 . often surrogate end points areu sed to keep the sample size as small as possible (both for practical and economical reasons), but in such acase it must be perfectly clear that there is a good correlation between the surrogate and some truly clinically relevant end point. otherwise surrogate endpoints areo bsolete. Af undamental ethical principle motivating an RCT is that therem ust be a true uncertainty of the relative effects of the alternatives. Basically, performing RCTs on pharmacological treatment is simple (double-blind, often placebo-controlled, correct pre-study sample size calculation, code broken after analysis of results when the predefined follow-up time has passed). The power of the RCT is that the risk of random or systematic (bias) error is minimized and the value of RCTs is of value also in surgery to avoid selection bias and confounding. The surgical trials are, however, faced with several rather specific problems, which must be dealt with (Table 3) . The reluctance often shown by surgeons can be handled by using the principle of "the grey area of uncertainty", which was introduced by Richardp eto and Charles Warlow when designing the ECST (3). for every individual surgeon it should be possible to identify patients, whereheorshe is not convinced how to treat, and in this situation randomization is the solution. However, the RCT study design has been considered difficult to perform in surgery.Asurgical trial can seldom be made blind with a sham operation, which is often used in animal experiments, and therefore a blinded adjudication of outcome and complications is mandatory. The placebo effect of surgery itself must be taken seriously. An independent safety board should also be included. As surgery is handicraft, there is always a learning curve, which includes not only learning technical details about the operation but also a continuous refinement in patient selection as well as in peri-and postoperative careincluding adjunctive pharmacological medication. obviously randomization can start too early,but by waiting too long the method may have been introduced without a proper scientific evaluation. Animportant problem is the much less economical funding to perform surgical trials compared to studies sponsored by the pharmaceutical industry. This is a challenge which should be taken very seriouslybygovernmental research councils andvarious funding organizations. However, the RCT study design has been considered difficult to perform in surgery. Some concerns have been mentioned such as unexpectedp athologiesa nd anatomical variations and that the surgeon is guided by a mixture of knowledge, experience, art, intuition and subliminal interaction, which would make standardization difficult. Every patient and operation is unique. However, those arguments should not prevent from randomization, on the contrary. Therea re some alternatives to conventional RCT, which may be useful. In the experience based RCT the patients arerandomized between the surgeons or the best departments performing the two methods to be compared (4). This seems reasonable from a methodological point of view and as far as patient safety is concerned, but on the other hand there will be logistic problems in transferring patients between hospitals, perhaps at a distance.
Another alternative model is the so called tracker study (5). This type of study combines advantages of registries and RCTsa nd is designed to track the progress of a study over time by having a flexible protocol and sophisticated interim analyses. The sample size is also open for alterations and is not prefixed. This model would seem recommendable when studying new devices and technologies, where modifications can be predicted to occur. So for instance theEVA R(endovascular aneurysm repair)technique started with no distal fixation resulting in severe endoleakage. Distal fixation was the logical solution. The next problem was proximal migration which forced adevelopment to equip the stents with hooks to make them stay in the vessel wall. Kinking tendency has been overcome by stent support along the whole graft. The problem with short necks has been handled with the aortic stent crossing the renal artery orifice, which does not seem to compromise renal function, or by stenting the renal artery. As imilar technical development is seen with carotid artery stenting, whereinitial results have been rather dismal (6-8). Due to cerebral complications from embolism, various protection devices have been developed. At the same time the so called best medical treatment is also improving, which will influence the sample size of further studies, the background stroke rate having diminished quite considerably. popUlATIon BASED REgISTRIES one important problem with RCTs is their sometimes poor or at least doubtful external validity,that is whether or notthe results from the studies can be generalized to the whole population with the clinical problem, which has been investigated. Another important factor is whether diffusion of a new technique outside awell defined study situation will by and by alter the indications and thereby perhaps also results and complications. Therefore introduction of new technologies should be carefully followed in population based registries, but one has to be aware of their strengths and weaknesses. one great advantage is the possibility to follow the new technique and results of it within the whole population of interest. Time trends can be analyzed and comparisons between departments, hospitals, and even countries can be undertaken. An example from the international registry Vascunet is the 30 day mortality after open elective surgery for aortic aneurysm, where most countries lie between 2-4% whereas UK has 8%. Such results must lead to further in depth analysis and can form the basis for important studies. The causes of time trends arecomplicated and difficult to analyze, and therecan be several changes in parallel, not all of them even known. The RCTso nc arotid endarterectomy in symptomatic patients with tight carotid artery stenosis werep ublished in 1991 and thus performed around 20 years ago. There are rea- sons to believe that best medical treatment as the background in patients with carotid artery disease has changed considerably during such along period. Such changes can at least theoretically be followed in a registry such as antiplatelet medication, antihypertensive treatment, use of statins, smoking habits etc. Moreover, rare outcomes, especially severe complications, can be detected in ar egistry,w hich they rarely areinanRCT. one example of ap opulation based registry is Swedvasc, the Swedish Vascular Registry. Swedvasc is now 20 years old and covers around 95% of all vascular surgery in Sweden. When results started to become official from the ACST (Asymptomatic Carotid Surgical Trial) (at meetings to begin with) endarterectomies for asymptomatic carotid artery stenosis increased in Sweden (from 2001 to 2005 amore than three-fold increase), and Swedvasc registry data showed results not inferior to those in the RCTs. So the 30 day permanent stroke and death rate was 1.4% (882 patients) (9,10), which can be compared with the results from ACAS (2.3% in 825 patients) and ACST (2.8% in 1560 patients). Another example is what happened when introducing anew coated polyester graft without inclusion into ar egistry or acommon protocol (11) . The detection of ah igh occlusion rate and withdrawal of the graft was probably delayed with great clinical consequences for individual patients.
EVIDEnCE fRoM SySTEMATIC lITERATURE STUDIES
Athird way that may be helpful is to systematically scrutinize all publications available regarding the new technology of interest. The questions to be asked are if the results are reliable, which is the size of the effect and if the results area pplicable in my clinical situation. If the therapeutic principle is relatively new and the pressure high to use it, a rather rapid way is a so called horizon scan, which should not take more than af ew months (for instance ASERnIps Horizon scan in Australia (12) , Alert reports from the Swedish Boardfor Health Technology Assessment).
The method of performing systematic literature reviews will not be discussed here, but a rather depressing (15) . With the usual quality criteria for the Swedish Board 203 papers (4.8%) remained after abstract reading and evidence grading was possible for 25 (sic!), none of which obtaining the highest degree of evidence. This means that a lot of effort and money are spent on investigations with poor study methodology, when focus, concentration and cooperation certainly would have increased evidence levels. It must be the obligation of funding bodies and the research community to perform the optimal studies, both from as cientific and an economical point of view.
CoMMEnTS
It is important to pose the relevant and well-defined scientific questions on any new technology and choose the proper study methodology.Theremust be good knowledge on the strengths and weaknesses of the evaluation methods used. Thereisnodoubt that the RCT design with prospective definition of the methods and outcomes, and an unbiased selection of subjects provide the best possible evidence for deciding the value and the magnitude of the effect of an intervention. If it is not possible to perform an RCT, alternative research designs may be considered, such as prospective matched-pair trials, expertise based RCT and tracker study design in combination with population based registries. If results from well-designed non-RCT favours a procedure it gives important information in favour of one method versus another but not on the magnitude of the effect, which must be considered exaggerated until proven otherwise. Investments must be used to optimize scientific information from a study. Much of what is written on technologies concerning vascular surgical patients is of limited quality. This is true for many types of surgery.
If as ystematic review is to be performed on the basis of allidentified RCTs, this isamethodologically and intellectually demanding process, and if a metaanalysis is to be undertaken, this is also amethod with strict methodological criteria which must be taken into account. 
ConClUSIon

